A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Abstract

As compared with placebo, both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI. These benefits will need to be weighed against possible long-term risks. (ClinicalTrials.gov number, NCT00289978.)